Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612320 | 1.00 | PDE2A (0.43) | PDE2ASLC6A4GSK3BMC4RCES2 | |
| SCHEMBL6391223 | 0.89 | PDE2A (0.41) | PDE2ASLC6A4GSK3BMC4RCES2 | |
| SCHEMBL18243484 | 0.85 | PDE2A (0.43) | PDE2ASLC6A4GSK3BMC4RCES2 | |
| SCHEMBL9337585 | 0.84 | PDE2A (0.46) | PDE2AGSK3BMC4RCES2CES1 | |
| SCHEMBL2316809 | 0.83 | PDE2A (0.42) | PDE2ASLC6A4GSK3BMC4RCES2 | |
| SCHEMBL15435343 | 0.82 | GRIA4 (0.45) | FFAR1 | |
| SCHEMBL16976289 | 0.80 | PDE2A (0.46) | PDE2ASLC6A4MC4RCES2CES1 | |
| SCHEMBL9187166 | 0.78 | PDE2A (0.44) | PDE2ASLC6A4MC4RCES2CES1 | |
| SCHEMBL2090318 | 0.78 | PDE2A (0.49) | PDE2ASLC6A4MC4RCES2CES1 | |
| SCHEMBL2125627 | 0.78 | ALDH1A1 (0.40) | SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | PSEN1, PSEN2, APP | PDE2A 1086/4885SLC6A4 766/4885GSK3B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.